Pemphigus
Conditions
Interventions
experimental group :Experimental group: 100 mg rituximab at week 0, week 2, and month 6 once, combined with glucocorticoid therapy
control group 1:Control group one: mycophenolate mofetil combined with glucocorticoid therapy.
control group 2:Control group two: 500 mg rituximab at week 0, week 2 once, combined with glucocorticoid therapy
Sponsors
Shandong Provincial Hospital for Skin Diseases & Shandong First Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients meeting the diagnostic criteria for pemphigus (a: clinical manifestations of flaccid vesicles and erosions on the skin and mucous membranes, positive Nissl sign; b histopathological examination showed intraepidermal blisters and acantholysis; c direct immunofluorescence Examination revealed IgG and C3 reticular deposition between spiny cells); 2. Adult patients aged 18-80; 3. Mild to severe pemphigus (PDAI (PemphigusDiseaseAreaIndex, Pemphigus Disease Area Index) score, 25 points as mild, moderate, and severe); 4. Receive RTX treatment for the first time; 5. Sign the informed consent; 6. Can receive treatment and follow-up as planned;
Exclusion criteria
Exclusion criteria: Patients who had previously received RTX or RTX for treatment of relapse; patients aged 80 years; patients with medication contraindications, including severe cardiovascular disease, severe liver and kidney damage, severe active infection, previous severe infusion reactions, history of severe allergy to related drugs, history of cancer, pregnant and lactating women, and recently vaccinated or planned vaccination.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission.;Complete remission off therapy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cumulative glucocorticoid dosage; | — |
Countries
China
Contacts
Public ContactZhang Furen
Shandong Provincial Hospital for Skin Diseases & Shandong First Medical University
Outcome results
None listed